ENDOSCOPE HOLDER (182214)

K261573 · Aktormed GmbH · QZB · Jul 20, 2026 · Gastroenterology, Urology

Device Facts

Record IDK261573
Device NameENDOSCOPE HOLDER (182214)
ApplicantAktormed GmbH
Product CodeQZB · Gastroenterology, Urology
Decision DateJul 20, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.1500
Device ClassClass 2

Indications for Use

For the ENDOSCOPE HOLDER as a component of the SOLOASSIST IIS the indications for use of the SOLOASSIST IIS applies. The intended use of the SOLOASSIST IIS is a robotic computer driven system whose function is to hold and position a rigid laparoscope / endoscope. The SOLOASSIST IIS is indicated for use in minimally invasive interventions where a rigid laparoscope / endoscope is indicated for use. Surgeries, SOLOASSIST IIS is used, are laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic pelvic lymph node dissection, laparoscopically assisted hysterectomy, laparoscopic & thorascopic, decompression fixation, wedge resection, lung biopsy, pleural biopsy, dorsal sympathectomy, pleurodesis, internal mammary artery dissection for coronary artery bypass, coronary artery bypass grafting where endoscopic visualization is indicated and examination of the evacuated cardiac chamber during performance of valve replacement. The users of the SOLOASSIST IIS are general surgeons, gynecologists, cardiac surgeons, thoracic surgeons and urologists.

Device Story

Endoscope Holder (182214) is a sterile, single-use component for the SOLOASSIST IIS robotic system; functions to hold and position rigid laparoscopes/endoscopes during minimally invasive surgery. Device comprises universal joint, clamp D5, clamp D10, and knurled nut with screw. Surgeon/clinician attaches holder to robotic arm; endoscope is threaded and secured via screw/clamp mechanism. Provides stable visualization for general, gynecological, cardiac, thoracic, and urological surgeons. Benefits include consistent endoscope positioning, reducing manual holding requirements during complex laparoscopic/thoracoscopic procedures. Replaces reusable components of predicate SOLOASSIST II with single-use materials; maintains identical functional attachment and load-bearing capabilities.

Clinical Evidence

No clinical data. Bench testing only: human factors testing (IEC 62366-1/60601-1-6), functional tests, load tests (IEC 60601-1), compatibility tests, clamping range tests, and packaging tests (ISTA 1A).

Technological Characteristics

Materials: MABS (main parts), PA66 (knurled nut). Principle: Mechanical screw/clamp fixation for rigid endoscopes. Sterilization: Ethylene Oxide (EO). Connectivity: Attaches to SOLOASSIST IIS robotic arm. Single-use, sterile. Dimensions/load capacity verified equivalent to predicate via bench testing.

Indications for Use

Indicated for use in minimally invasive surgical interventions requiring rigid laparoscope/endoscope positioning. Patient population includes adults undergoing procedures such as laparoscopic cholecystectomy, hernia repair, appendectomy, pelvic lymph node dissection, hysterectomy, thoracic surgeries (wedge resection, lung/pleural biopsy, dorsal sympathectomy, pleurodesis), and cardiac procedures (coronary artery bypass grafting, valve replacement).

Regulatory Classification

Identification

An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.

Special Controls

*Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.

In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls: 1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following: 1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures. 2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use. 3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use. 2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes. 3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches 4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error. 5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program. (6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms. (7) Labeling must include: (i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified; (ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA; (iii) Identification of compatible devices; (iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification; (v) Reprocessing instructions for reusable components; (vi) A shelf life for any sterile components; (vii) A description of the device-specific use training program; (viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and (ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance. (8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include: (i) Device motion accuracy and repeatability; (ii) System testing; (iii) Instrument reliability; (iv) Crosstalk; (v) Table motion control; (vi) Thermal effects on tissue; (vii) User-device interface performance; (viii) Workspace access testing; and (ix) Performance testing with compatible devices. (9) Software verification, validation, and hazard analysis must be performed. (10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed. (11) Performance data must demonstrate the sterility of all patient-contacting device components. (12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life. (13) Performance data must validate the reprocessing instructions for the reusable components of the device. (14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible. (15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic. (16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information: (i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and (ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period.

Predicate Devices

Submission Summary (Full Text)

{0} **U.S. FOOD & DRUG** ADMINISTRATION July 20, 2026 Aktormed GmbH Hanna Kafurke QM/ Regulatory Affairs Manager Neugablonzer Strasse 13 Neutraubling, BY 93073 Germany Re: K261573 Trade/Device Name: Endoscope Holder (182214) Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope And Accessories Regulatory Class: Class II Product Code: QZB Dated: May 12, 2026 Received: May 12, 2026 Dear Hanna Kafurke: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K261573 - Hanna Kafurke Page 2 (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). {2} K261573 - Hanna Kafurke Page 3 Sincerely, MARK TRUMBORE -S Digitally signed by MARK TRUMBORE -S Date: 2026.07.20 09:49:33 -04'00' Mark Trumbore, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | | ? | | Please provide the device trade name(s). | | ? | | ENDOSCOPE HOLDER (182214) | | | | Please provide your Indications for Use below. | | ? | | For the ENDOSCOPE HOLDER as a component of the SOLOASSIST IIS the indications for use of the SOLOASSIST IIS applies.The intended use of the SOLOASSIST IIS is a robotic computer driven system whose function is to hold and position a rigid laparoscope / endoscope.The SOLOASSIST IIS is indicated for use in minimally invasive interventions where a rigid laparoscope / endoscope is indicated for use. Surgeries, SOLOASSIST IIS is used, are laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic pelvic lymph node dissection, laparoscopically assisted hysterectomy, laparoscopic & thorascopic, decompression fixation, wedge resection, lung biopsy, pleural biopsy, dorsal sympathectomy, pleurodesis, internal mammary artery dissection for coronary artery bypass, coronary artery bypass grafting where endoscopic visualization is indicated and examination of the evacuated cardiac chamber during performance of valve replacement.The users of the SOLOASSIST IIS are general surgeons, gynecologists, cardiac surgeons, thoracic surgeons and urologists. | | | | Please select the types of uses (select one or both, as applicable). | Prescription Use (21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | Neonates/Newborns (Birth to < 29 days old)Infants (29 days old to < 2 years old)Children (2 years old to < 12 years old)Adolescents (12 years old to < 22 years old)Adults (22 years old and greater) | ? | {4} 510(k) #: # 510(k) Summary Prepared on: 2026-05-07 ## Contact Details 21 CFR 807.92(a)(1) Applicant Name AKTORmed GmbH Applicant Address Neugablonzer Strasse 13 Neutraubling BY 93073 Germany Applicant Contact Telephone +4994019320150 Applicant Contact Mrs. Hanna Kafurke Applicant Contact Email regulatory@aktormed.com ## Device Name 21 CFR 807.92(a)(2) Device Trade Name ENDOSCOPE HOLDER (182214) Common Name Endoscope and accessories Classification Name Software Controlled Endoscope And Instrument Holder Regulation Number 876.1500 Product Code(s) QZB ## Legally Marketed Predicate Devices 21 CFR 807.92(a)(3) Predicate # Predicate Trade Name (Primary Predicate is listed first) Product Code K233312 UNIVERSAL JOINT, ENDOSCOPE CLAMP, TENSION SLEEVE D5, TENSION SLEEVE D10 QZB ## Device Description Summary 21 CFR 807.92(a)(4) The ENDOSCOPE HOLDER is a sterile disposable product that will be attached to the SOLOASSIST IIS to hold a rigid endoscope/laparoscope. The SOLOASSIST IIS is technically identical to SOLOASSIST II from K233312 (see Letter to file - SOLOASSIST IIS) The ENDOSCOPE HOLDER consists of 3 main parts (UNIVERSAL JOINT, CLAMP D5 and CLAMP D10). A KNURLED NUT with a screw is used together with the parts to tighten the CLAMPs and therefore fix the laparoscope / endoscope. The main parts are made of MABS, the KNURLED NUT of PA66. All parts are packed together and are sterilized with EO. The product is a sterile device for single use. Functionally, it has the same task as the components of the SOLOASSIST II from K233312 named UNIVERSAL JOINT (REF: 141362), ENDOSCOPE CLAMP (REF: 141363), and TENSION SLEEVES (REF: 141339 and 141365). The main difference is the reusability as the SOLOASSIST II components are reprocessable while the ENDOSCOPE HOLDER is single use. ## Intended Use/Indications for Use 21 CFR 807.92(a)(5) For the ENDOSCOPE HOLDER as a component of the SOLOASSIST IIS the indications for use of the SOLOASSIST IIS applies. The intended use of the SOLOASSIST IIS is a robotic computer driven system whose function is to hold and position a rigid laparoscope / endoscope. The SOLOASSIST IIS is indicated for use in minimally invasive interventions where a rigid laparoscope / endoscope is indicated for use. Surgeries, SOLOASSIST IIS is used, are laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic pelvic lymph node dissection, laparoscopically assisted hysterectomy, laparoscopic & thorascopic, decompression fixation, wedge resection, lung biopsy, pleural biopsy, dorsal sympathectomy, pleurodesis, internal mammary artery dissection for coronary artery bypass, coronary artery bypass grafting where endoscopic visualization is indicated and examination of the evacuated cardiac chamber during performance of valve replacement. {5} The users of the SOLOASSIST IIS are general surgeons, gynecologists, cardiac surgeons, thoracic surgeons and urologists. ## Indications for Use Comparison 21 CFR 807.92(a)(5) The indications for use of the ENDOSCOPE HOLDER are the same as for the predicate device. ## Technological Comparison 21 CFR 807.92(a)(6) From a functional point of view, the endoscope holding components (ENDOSCOPE HOLDER with UNIVERSAL JOINT and CLAMPs) for SOLOASSIST IIS are almost identical to the already approved components (UNIVERSAL JOINT, ENDOSCOPE CLAMP, TENSION SLEEVES) for SOLOASSIST II (K233312). The functionality of the UNIVERSAL JOINT component of the ENDOSCOPE HOLDER is comparable to that of the UNIVERSAL JOINT of the SOLOASSIST II. Both UNIVERSAL JOINTs are attached to the arm system through the STERILE COVER. The attachment and release mechanisms are identical. In addition, both have a plug connection to the endoscope-holding components. Touching the trocar point with the tips is also done in the same way. The CLAMPs are comparable to the ENDOSCOPE CLAMP in combination with the TENSION SLEEVES. In both variants, the endoscope is threaded on and secured using a screw and clamp mechanism. The minor differences in the connections between the components due to design differences were thoroughly tested in a usability study and found to be at least as safe. Both endoscope-holding connections can bear the same working load. The different mechanical load capacities resulting from the different components and materials used were classified as at least equally safe in corresponding bench tests, meaning that the same working load can be achieved. In terms of dimensions, both connections are similar and differ only slightly due to design. The following points force the technological differences between the models. The main difference is the reusability of the components. While the ENDOSCOPE HOLDER is supplied sterile and is for single use only, the components for SOLOASSIST II are reprocessible and therefore reusable. Due to the different manufacturing process and desired reusability, different materials were used. The materials of the ENDOSCOPE HOLDER were sufficiently tested for their suitability in terms of EO sterilization, packaging and shelf life and were found to be at least as safe. Proof of sufficient safety with regard to biocompatibility is available. The choice of other materials therefore also leads to differences in weight. Differences in the clamping range are due to the different components. Suitable endoscope diameters were verified in corresponding bench tests. ## Non-Clinical and/or Clinical Tests Summary & Conclusions 21 CFR 807.92(b) The following non-clinical tests were carried out to demonstrate that the new device is as equally safe and effective as the predicate devices. The test results from K233312 cannot be applied to the new products because the products differ in terms of materials, manufacturing and also a bit about how to use it. So new tests were conducted: Human factor testing according to IEC 62366-1/60601-1-6, functional tests, load tests based on IEC 60601-1, compatibility tests, clamping range tests, reuseability tests and packaging tests based on ISTA 1A. Not Applicable The non-clinical tests have shown that the ENDOSCOPE HOLDER is as safe and effective as the predicate devices.
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...